Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DermTech International

www.dermtech.com

Latest From Kadmon Corp. LLC

US IPOs In Review: Relatively Muted Market In 2016 To Continue In 2017

After biopharma initial public offerings in the US during 2016 outperformed the prior year’s IPOs, expect more of the same in 2017: fewer, but higher quality offerings at lower IPO share prices to keep values at acceptable levels for experienced health care investors.

StartUps and SMEs Financing

IPO Update: TiGenix Debuts In December After Motif Launched In November As 2016 Offerings Best 2015

Motif Bio and TiGenix were the 29th and 30th biopharma IPOs in 2016 with the only first-time offerings for November and so far in December, but looking at performance so far this year, IPOs by therapeutics firms in 2016 continue to outperform 2015 offerings.

Commercial Financing

Pipeline Watch: Phase III Results With Tagrisso, Biosimilar Rituximab And Vonvendi

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals

Pipeline Watch: Phase III Starts With Filgotinib, Gilteritinib And Nivolumab

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Clinical Trials
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Laboratory Testing Services
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Services
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Inflammation
  • Alias(es)
  • DermTech Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • DermTech International
  • Senior Management
  • John Dobak, MD, Pres. & CEO
    Steven Kemper, CFO
    John Alsobrook, PhD, CSO
  • Contact Info
  • DermTech International
    Phone: (858) 450-4222
    11099 N. Torrey Pines Rd.
    Ste. 100
    La Jolla, CA 92037
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register